Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan
· Delayed Price · Currency is TWD 32.00
+0.35 (1.11%)
Mar 10, 2026, 12:50 PM CST
TPEX:7427 Revenue
Great Novel Therapeutics Biotech & Medicals had revenue of 623.00K TWD in the half year ending June 30, 2025, a decrease of -86.92%. This brings the company's revenue in the last twelve months to 1.78M, up 189.59% year-over-year. In the year 2024, Great Novel Therapeutics Biotech & Medicals had annual revenue of 1.69M, down -65.26%.
Revenue (ttm)
1.78M
Revenue Growth
+189.59%
P/S Ratio
763.29
Revenue / Employee
118.73K
Employees
15
Market Cap
1.36B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 486.52M |
| Abnova (Taiwan) | 351.30M |
| NeoCore Technology | 190.10M |
| GenMont Biotech Incorporation | 391.48M |
| Enimmune | 42.23M |
| GeneReach Biotechnology | 215.32M |
| Genomics BioSci & Tech. | 607.89M |
| Lukas Biomedical | 180.32M |